Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (843) 843
Publication (154) 154
Book Review (96) 96
Conference Proceeding (35) 35
Newspaper Article (29) 29
Book / eBook (27) 27
Web Resource (20) 20
Patent (18) 18
Book Chapter (15) 15
Dissertation (4) 4
Magazine Article (3) 3
Newsletter (3) 3
Report (3) 3
Reference (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (491) 491
humans (458) 458
hematology (297) 297
female (235) 235
male (228) 228
middle aged (218) 218
oncology (215) 215
adult (208) 208
aged (174) 174
abridged index medicus (140) 140
treatment outcome (127) 127
chemotherapy (107) 107
antineoplastic agents - therapeutic use (102) 102
prognosis (93) 93
cancer (92) 92
antineoplastic combined chemotherapy protocols - therapeutic use (88) 88
remission induction (88) 88
adolescent (85) 85
article (85) 85
acute myeloid-leukemia (78) 78
leukemia, promyelocytic, acute - drug therapy (77) 77
therapy (75) 75
aged, 80 and over (70) 70
trans-retinoic acid (68) 68
young adult (68) 68
acute promyelocytic leukemia (67) 67
leukemia (64) 64
acute myelogenous leukemia (62) 62
acute myeloid leukemia (60) 60
survival analysis (60) 60
leukemia, myeloid, acute - drug therapy (58) 58
transplantation (55) 55
disease-free survival (53) 53
arsenic trioxide (51) 51
mutation (51) 51
hematology, oncology and palliative medicine (49) 49
recurrence (49) 49
analysis (48) 48
hemic and lymphatic diseases (48) 48
survival rate (47) 47
animals (45) 45
leukemia, myeloid, acute - genetics (45) 45
research (42) 42
hematopoietic stem cell transplantation (41) 41
tretinoin - therapeutic use (41) 41
acute disease (38) 38
antineoplastic agents - adverse effects (38) 38
leukemia, myeloid, acute - therapy (38) 38
risk factors (38) 38
stem-cell transplantation (38) 38
survival (38) 38
bone-marrow-transplantation (37) 37
minimal residual disease (34) 34
follow-up studies (33) 33
remission (33) 33
retrospective studies (33) 33
cytarabine - administration & dosage (32) 32
clinical trials and observations (31) 31
leukemia, myeloid, acute - mortality (31) 31
antineoplastic combined chemotherapy protocols - adverse effects (30) 30
clinical trials as topic (30) 30
cytogenetics (30) 30
child (29) 29
christianity (29) 29
neurology (29) 29
time factors (29) 29
arsenicals - therapeutic use (28) 28
leukemia, myeloid, acute - diagnosis (28) 28
leukemia, promyelocytic, acute - mortality (28) 28
relapse (28) 28
clinical trials (27) 27
immunology (27) 27
oxides - therapeutic use (27) 27
daunorubicin - administration & dosage (26) 26
aml (25) 25
expression (25) 25
protestant reformation (25) 25
transplantation, homologous (25) 25
trial (25) 25
care and treatment (24) 24
differentiation (24) 24
health aspects (24) 24
cladribine - therapeutic use (23) 23
genetic aspects (23) 23
mice (23) 23
religious organizations (23) 23
tretinoin - administration & dosage (23) 23
all-trans retinoic acid (22) 22
child, preschool (22) 22
hematopoietic stem cell transplantation - methods (22) 22
risk (22) 22
spirituality (22) 22
antineoplastic combined chemotherapy protocols - administration & dosage (21) 21
complete remission (21) 21
induction chemotherapy (21) 21
leukemia, promyelocytic, acute - complications (21) 21
adults (20) 20
antineoplastic agents - administration & dosage (20) 20
bone marrow - pathology (20) 20
cells (20) 20
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Robarts - Stacks (9) 9
UTL at Downsview - May be requested (4) 4
Gerstein Science - Stacks (3) 3
Online Resources - Online (2) 2
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Indust. Rel's & Hum. Resources (Newman) - Library use only (1) 1
Knox College (Caven) - Stacks (1) 1
Law (Bora Laskin) - Stacks (1) 1
OISE - WERC (1) 1
Thomas Fisher Rare Book - Rare Book (1) 1
UofT at Mississauga - Stacks (1) 1
Victoria University E.J. Pratt - Stacks (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Immune therapy in haematological malignancies
by Tallman, Martin S
2006, Best practice & research. Clinical haematology, Volume 19, no. 4., 635-847
Treatment | Hematological oncology
Book
Details down arrow
2. Acute promyelocytic leukaemia
by Tallman, Martin S
2003, Best practice & research., Volume 16, no. 3., vii, 347-543, iii p.
Hematology | Blood | Diseases
Book
Details down arrow
3. Advancing the treatment of hematologic malignancies through the development of targeted interventions
by Tallman, Martin S
2002, Seminars in hematology, Volume 39, no. 4, suppl. 3., 37
Book
Details down arrow
4. Full Text Editorial introduction
by Tallman, Martin S
Current Opinion in Hematology, ISSN 1065-6251, 03/2015, Volume 22, Issue 2, p. v
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Exciting Times in Acute Myeloid Leukemia
by Tallman, Martin S
Seminars in Hematology, ISSN 0037-1963, 04/2019, Volume 56, Issue 2, pp. 83 - 83
HEMATOLOGY
Journal Article
Details down arrow
6. Hairy cell leukemia
by Polliack, Aaron, 1939 and Tallman, Martin S
2000, Advances in blood disorders, ISBN 9789058230096, Volume 5, xiii, 189
Leukemia, Hairy Cell | Treatment
Book
Details down arrow
7. Diagnostic and therapeutic advances in hematologic malignancies
by Gordon, Leo I and Tallman, Martin S
1999, Cancer treatment and research, ISBN 9780792382065, Volume 99, x, 377
diagnosis | Lymphoproliferative disorders | Hematologic Neoplasms | Molecular aspects | therapy
Book
Details down arrow
8. Full Text The Role of Abnormal Hemostasis and Fibrinolysis in Morbidity and Mortality of Acute Promyelocytic Leukemia
by Kwaan, Hau C and Weiss, Ivy and Tallman, Martin S
Seminars in Thrombosis and Hemostasis, ISSN 0094-6176, 09/2019, Volume 45, Issue 6, pp. 612 - 621
Abstract Despite the improved therapeutic advances in the management of acute promyelocytic leukemia (APL), a significant early mortality during induction,... 
Review Article | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text How I treat acute promyelocytic leukemia
by Tallman, Martin S and Altman, Jessica K
Blood, ISSN 0006-4971, 12/2009, Volume 114, Issue 25, pp. 5126 - 5135
Acute promyelocytic leukemia is the first malignant disease highly curable with targeted therapy directed at a unique molecular abnormality. The characteristic... 
ARSENIC TRIOXIDE THERAPY | SINGLE-CENTER EXPERIENCE | MOLECULAR REMISSION | APL GROUP EXPERIENCE | REMISSION INDUCTION THERAPY | PROGNOSTIC-FACTORS | TRANS-RETINOIC ACID | RAR-ALPHA | HEMATOLOGY | MYELODYSPLASTIC SYNDROME | GEMTUZUMAB-OZOGAMICIN | Oxides - therapeutic use | Tretinoin - administration & dosage | Outcome Assessment (Health Care) | Humans | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Reverse Transcriptase Polymerase Chain Reaction | Bone Marrow Examination | Dose-Response Relationship, Drug | Arsenicals - administration & dosage | Arsenicals - therapeutic use | Tretinoin - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Oncogene Proteins, Fusion - genetics | Leukemia, Promyelocytic, Acute - diagnosis | Leukemia, Promyelocytic, Acute - genetics | Oxides - administration & dosage | Leukemia, Promyelocytic, Acute - drug therapy | Practice Guidelines as Topic | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text How I treat extramedullary acute myeloid leukemia
by Bakst, Richard L and Tallman, Martin S and Douer, Dan and Yahalom, Joachim
Blood, ISSN 0006-4971, 10/2011, Volume 118, Issue 14, pp. 3785 - 3793
Extramedullary (EM) manifestations of acute leukemia include a wide variety of clinically significant phenomena that often pose therapeutic dilemmas. Myeloid... 
ACUTE MONOBLASTIC LEUKEMIA | BONE-MARROW-TRANSPLANTATION | ACUTE MYELOGENOUS LEUKEMIA | CENTRAL-NERVOUS-SYSTEM | TRANS-RETINOIC ACID | OF-THE-LITERATURE | STEM-CELL TRANSPLANTATION | HEMATOLOGY | GRANULOCYTIC SARCOMA CHLOROMA | ACUTE MYELOBLASTIC-LEUKEMIA | ACUTE PROMYELOCYTIC LEUKEMIA | Sarcoma, Myeloid - pathology | Leukemic Infiltration - genetics | Sarcoma, Myeloid - genetics | Prognosis | Leukemia, Myeloid, Acute - pathology | Humans | Drug Therapy | Hematopoietic Stem Cell Transplantation | Sarcoma, Myeloid - complications | Leukemic Infiltration - complications | Leukemia, Myeloid, Acute - complications | Chromosome Aberrations | Leukemic Infiltration - pathology | Sarcoma, Myeloid - therapy | Mutation | Leukemia, Myeloid, Acute - therapy | Leukemic Infiltration - therapy | Skin - pathology | Leukemia, Myeloid, Acute - genetics | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text How I treat acute myeloid leukemia
by Rowe, Jacob M and Tallman, Martin S
Blood, ISSN 0006-4971, 10/2010, Volume 116, Issue 17, pp. 3147 - 3156
More than one quarter of a million adults throughout the world are diagnosed annually with acute myeloid leukemia (AML). Despite considerable progress during... 
ADULT PATIENTS | ACUTE NONLYMPHOCYTIC LEUKEMIA | BONE-MARROW-TRANSPLANTATION | ACUTE MYELOGENOUS LEUKEMIA | ACUTE NONLYMPHOBLASTIC LEUKEMIA | COUNCIL AML11 TRIAL | STEM-CELL TRANSPLANTATION | DOSE CYTOSINE-ARABINOSIDE | HEMATOLOGY | 1ST COMPLETE REMISSION | COOPERATIVE-ONCOLOGY-GROUP | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Remission Induction | Transplantation, Homologous | Leukemia, Myeloid, Acute - diagnosis | Survival Analysis | Cytogenetics | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Aged | Leukemia, Myeloid, Acute - therapy | Leukemia, Myeloid, Acute - genetics | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
by Stone, Richard M and Mandrekar, Sumithra J and Sanford, Ben L and Laumann, Kristina and Geyer, Susan and Bloomfield, Clara D and Thiede, Christian and Prior, Thomas W and Döhner, Hartmut and Döhner, Konstanze and Marcucci, Guido and Lo-Coco, Francesco and Klisovic, Rebecca B and Wei, Andrew and Sierra, Jorge and Sanz, Miguel A and Brandwein, Joseph M and de Witte, Theo and Niederwieser, Dietger and Appelbaum, Frederick R and Medeiros, Bruno C and Tallman, Martin S and Krauter, Jürgen and Schlenk, Richard F and Ganser, Arnold and Serve, Hubert and Ehninger, Gerhard and Amadori, Sergio and Larson, Richard A
The New England Journal of Medicine, ISSN 0028-4793, 08/2017, Volume 377, Issue 5, pp. 454 - 464
Midostaurin, an oral multitargeted kinase inhibitor, is active in patients with a FLT3 mutation. Among patients with acute myeloid leukemia and this mutation,... 
TRIAL | INTERNAL TANDEM DUPLICATION | WILD-TYPE | MEDICINE, GENERAL & INTERNAL | FAVORABLE PROGNOSIS | ACUTE MYELOGENOUS LEUKEMIA | DISTINCT | TYROSINE KINASE INHIBITOR | SORAFENIB | PHASE-I | YOUNGER | Humans | Middle Aged | Kaplan-Meier Estimate | Staurosporine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Staurosporine - analogs & derivatives | Protein Kinase Inhibitors - adverse effects | Cytarabine - administration & dosage | Leukemia, Myeloid, Acute - mortality | Young Adult | fms-Like Tyrosine Kinase 3 - genetics | Protein Kinase Inhibitors - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Mutation | Daunorubicin - administration & dosage | Leukemia, Myeloid, Acute - genetics | Staurosporine - administration & dosage | Chemotherapy | Care and treatment | Myelocytic leukemia | Nonlymphoid leukemia | Research | Drug therapy | Cancer | Tyrosine | Medical research | Inhibitor drugs | Myeloid leukemia | Leukemia | Clinical trials | Oncology | Transplantation | Kinases | Patients | Cancer therapies | Survival | Cytarabine | Daunorubicin | Medical prognosis | Point mutation | Death | Remission | Acute myeloid leukemia | Protein-tyrosine kinase | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text The best of times in hematologic malignancies
by Tallman, Martin S
Current Opinion in Hematology, ISSN 1065-6251, 03/2015, Volume 22, Issue 2, pp. 75 - 76
HEMATOLOGY | Hematologic Neoplasms - therapy | Hematologic Neoplasms - diagnosis | Humans | Hematologic Neoplasms - etiology | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Current Opinion in Hematology: Editorial introduction
by Tallman, Martin S
Current Opinion in Hematology, ISSN 1065-6251, 03/2011, Volume 18, Issue 2
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia
by Robert J. Kreitman and Martin S. Tallman and Tadeusz Robak and Steven Coutre and Wyndham H. Wilson and Maryalice Stetler-Stevenson and David J. FitzGerald and Robert Lechleider and Ira Pastan
Journal of Clinical Oncology, ISSN 0732-183X, 05/2012, Volume 30, Issue 15, pp. 1822 - 1828
Purpose To conduct a phase I dose-escalation trial assessing safety and response of recombinant immunotoxin moxetumomab pasudotox (CAT-8015, HA22) in... 
PENTOSTATIN | COMPLETE REMISSION | ONCOLOGY | RFB4(DSFV)-PE38 BL22 | TERM-FOLLOW-UP | 2-CHLORODEOXYADENOSINE | ERADICATION | SINGLE COURSE | MINIMAL RESIDUAL DISEASE | HEMATOLOGIC MALIGNANCIES | CLADRIBINE | Leukemia, Hairy Cell - immunology | Immunotherapy - methods | Humans | Middle Aged | Leukemia, Hairy Cell - therapy | Drug Resistance, Neoplasm | Male | Sialic Acid Binding Ig-like Lectin 2 - immunology | Treatment Outcome | Bacterial Toxins - adverse effects | Exotoxins - adverse effects | Bacterial Toxins - therapeutic use | Immunotherapy - adverse effects | Disease-Free Survival | Exotoxins - therapeutic use | Time Factors | Adult | Female | Aged | Leukemia, Hairy Cell - pathology | Index Medicus | Creatinine | Edema | Headache | Hemolytic uremic syndrome | Toxicity | Antibodies | Clinical trials | Cytotoxicity | Fatigue | Nausea | Survival | Blood | Hypotension | Immunotoxins | Hairy cell leukemia | Immunogenicity | Remission | Platelets | Hema7 | Original Reports
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text Acute promyelocytic leukemia
by Tallman, Martin S., M.D
Best Practice & Research: Clinical Haematology, ISSN 1521-6926, 2014, Volume 27, Issue 1, pp. 1 - 1
Hematology, Oncology and Palliative Medicine | Humans | Leukemia, Promyelocytic, Acute | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
17. Full Text Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
by Patel, Jay P and Gönen, Mithat and Figueroa, Maria E and Fernandez, Hugo and Sun, Zhuoxin and Racevskis, Janis and Van Vlierberghe, Pieter and Dolgalev, Igor and Thomas, Sabrena and Aminova, Olga and Huberman, Kety and Cheng, Janice and Viale, Agnes and Socci, Nicholas D and Heguy, Adriana and Cherry, Athena and Vance, Gail and Higgins, Rodney R and Ketterling, Rhett P and Gallagher, Robert E and Litzow, Mark and van den Brink, Marcel R.M and Lazarus, Hillard M and Rowe, Jacob M and Luger, Selina and Ferrando, Adolfo and Paietta, Elisabeth and Tallman, Martin S and Melnick, Ari and Abdel-Wahab, Omar and Levine, Ross L
The New England Journal of Medicine, ISSN 0028-4793, 03/2012, Volume 366, Issue 12, pp. 1079 - 1089
Malignant cells in most patients with acute myeloid leukemia have mutations. Cytogenetic classification yields some prognostic information, but the... 
AML | MEDICINE, GENERAL & INTERNAL | IDENTIFY | OLDER PATIENTS | DNMT3A | NORMAL CYTOGENETICS | TET2 | YOUNGER ADULTS | MUTATIONS | Gene Duplication | Risk Assessment - methods | Translocation, Genetic | Prognosis | DNA Fingerprinting | Humans | Middle Aged | Kaplan-Meier Estimate | Induction Chemotherapy | Antibiotics, Antineoplastic - administration & dosage | Leukemia, Myeloid, Acute - mortality | Young Adult | DNA Mutational Analysis | Adolescent | Leukemia, Myeloid, Acute - drug therapy | Adult | Mutation | Daunorubicin - administration & dosage | Leukemia, Myeloid, Acute - genetics | Studies | Translocation | Medical research | Chemotherapy | Daunorubicin | Myeloid leukemia | Clinical trials | Remission | Acute myeloid leukemia | Patients | Deoxyribonucleic acid--DNA | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
18. Full Text Antibody-based therapy in acute leukemia - beware the risks
by Stahl, Maximilian and Tallman, Martin S
Leukemia & Lymphoma, ISSN 1042-8194, 06/2019, Volume 60, Issue 7, pp. 1608 - 1609
ADULT PATIENTS | GEMTUZUMAB OZOGAMICIN | PROFILE | ONCOLOGY | INOTUZUMAB OZOGAMICIN | OPEN-LABEL | BLINATUMOMAB | HEMATOLOGY | CHEMOTHERAPY
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
19. Full Text Immunotherapy for acute myeloid leukemia: from allogeneic stem cell transplant to novel therapeutics
by Knorr, David A and Goldberg, Aaron D and Stein, Eytan M and Tallman, Martin S
Leukemia & lymphoma, ISSN 1042-8194, 07/2019, pp. 1 - 13
Immunotherapy in the form of allogeneic stem cell transplantation (SCT) plays an instrumental role in the treatment of acute myeloid leukemia (AML), with... 
Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
20. Full Text A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia
by Petersdorf, Stephen H and Petersdorf, Stephen H and Kopecky, Kenneth J and Kopecky, Kenneth J and Slovak, Marilyn and Slovak, Marilyn and Willman, Cheryl and Willman, Cheryl and Nevill, Thomas and Nevill, Thomas and Brandwein, Joseph and Brandwein, Joseph and Larson, Richard A and Larson, Richard A and Erba, Harry P and Erba, Harry P and Stiff, Patrick J and Stiff, Patrick J and Stuart, Robert K and Stuart, Robert K and Walter, Roland B and Walter, Roland B and Tallman, Martin S and Tallman, Martin S and Stenke, Leif and Stenke, Leif and Appelbaum, Frederick R and Appelbaum, Frederick R
Blood, ISSN 0006-4971, 06/2013, Volume 121, Issue 24, pp. 4854 - 4860
This randomized phase 3 clinical trial evaluated the potential benefit of the addition of gemtuzumab ozogamicin (GO) to standard induction and... 
SURVIVAL | EFFICACY | SAFETY | ANTIBODY | OUTCOMES | HEMATOLOGY | CHEMOTHERAPY | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Induction Chemotherapy | Male | Survival Rate | Consolidation Chemotherapy | Cytarabine - administration & dosage | Leukemia, Myeloid, Acute - mortality | Disease-Free Survival | Antibodies, Monoclonal, Humanized - administration & dosage | Aminoglycosides - administration & dosage | Adolescent | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Daunorubicin - administration & dosage | Index Medicus | Abridged Index Medicus | Clinical Trials and Observations | Farmakologi och toxikologi | Hematologi | Klinisk medicin | Medicin och hälsovetenskap | Medicinska och farmaceutiska grundvetenskaper | Cancer och onkologi
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.